Cited by 113Lymphatic System and DiseasesAngiogenesis and VEGF in CancerLymphatic Disorders and Treatments

Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression

Open access
Korhonen, Emilia A., Murtomäki, Aino, Jha, Sawan Kumar, Anisimov, Andrey, Pink, Anne, Zhang, Yan, Stritt, Simon, Liaqat, Inam +15 more·2022·Journal of Clinical Investigation

Abstract

Vascular endothelial growth factor C (VEGF-C) induces lymphangiogenesis via VEGF receptor 3 (VEGFR3), which is encoded by the most frequently mutated gene in human primary lymphedema. Angiopoietins (Angs) and their Tie receptors regulate lymphatic vessel development, and mutations of the ANGPT2 gene were recently found in human primary lymphedema. However, the mechanistic basis of Ang2 activity in lymphangiogenesis is not fully understood. Here, we used gene deletion, blocking Abs, transgene induction, and gene transfer to study how Ang2, its Tie2 receptor, and Tie1 regulate lymphatic vessels. We discovered that VEGF-C-induced Ang2 secretion from lymphatic endothelial cells (LECs) was involved in full Akt activation downstream of phosphoinositide 3 kinase (PI3K). Neonatal deletion of genes encoding the Tie receptors or Ang2 in LECs, or administration of an Ang2-blocking Ab decreased VEGFR3 presentation on LECs and inhibited lymphangiogenesis. A similar effect was observed in LECs upon deletion of the PI3K catalytic p110α subunit or with small-molecule inhibition of a constitutively active PI3K located downstream of Ang2. Deletion of Tie receptors or blockade of Ang2 decreased VEGF-C-induced lymphangiogenesis also in adult mice. Our results reveal an important crosstalk between the VEGF-C and Ang signaling pathways and suggest new avenues for therapeutic manipulation of lymphangiogenesis by targeting Ang2/Tie/PI3K signaling.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci155478

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Korhonen, E. A., Murtomäki, A., Jha, S. K., Anisimov, A., Pink, A., Zhang, Y., Stritt, S., Liaqat, I., Stanczuk, L., Alderfer, L., Sun, Z., Kapiainen, E., Singh, A., Sultan, I., Lantta, A., Leppänen, V.-M., Eklund, L., He, Y., Augustin, H. G., Vaahtomeri, K., Saharinen, P., Mäkinen, T., & Alitalo, K.
Affiliations
  • University of Helsinki (FI)
  • Uppsala University (SE)
  • University of Notre Dame (US)
  • Soochow University (CN)
  • University of Oulu (FI)
  • German Cancer Research Center (DE)
Corresponding author
Alitalo, Kari
Venue
Journal of Clinical Investigation
Published
2022-08-01
Volume
132
Issue
15
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4283644123
Cited by
113
References
68
Citations by year
2026: 32 · 2025: 32 · 2024: 30 · 2023: 17 · 2022: 2
FWCI
8.47
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
  • European Union’s Horizon 2020 research and innovation programme under grant agreement (874708)
  • Novo Nordisk Foundation (NNF16OC0023554)
  • Academy of Finland Centre of Excellence Program (307366)
  • Academy of Finland Research Costs of Academy Professor (312516)
  • Knut and Alice Wallenberg Foundation (2018.0218)
  • Swedish Research Council (2020-02692)
Topics
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
Keywords
lymphangiogenesis, angiopoietin-2, Tie2 receptor, VEGFR-3, VEGF-C, PI3K/Akt signaling, lymphatic endothelial cells, primary lymphedema, lymphatic development, signaling crosstalk
MeSH terms
Animals, Humans, Lymphedema, Ribonuclease, Pancreatic, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factor Receptor-3, Vascular Endothelial Growth Factor C, Lymphangiogenesis, Receptors, TIE, Endothelial Cells, Receptor, TIE-2, Mice, Phosphatidylinositol 3-Kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review